GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
Eligible age
18–99 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.
Sponsor: University of Arizona
You may qualify if…
- ✓ Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the "additional HCC cohort criteria" below.
- ✓ The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)
- ✓ Measurable disease per RECIST v1.1 as determined by the investigator
- ✓ Patients must be appropriate candidates for first-line, SOC treatment.
- ✓ SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to:
- ✓ Colorectal: FOLFOX or FOLIFIRI +/- bevacizumab
- ✓ Pancreatic: mFOLFIRINOX
- ✓ HCC: Tremelimumab/Durvalumab
You may not qualify if…
- ✕ The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and/or unresectable disease.
- ✕ BMI \< 25 kg/m2
- ✕ For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors.
- ✕ For colorectal cancer only - BRAF V600E mutant tumors.
- ✕ A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- ✕ A prior hypersensitivity reaction to semaglutide or any of the excipients in WEGOVY®. Serious hypersensitivity reaction, including anaphylaxis and angioedema, have been reported with WEGOVY®.
- ✕ Cachexia
- ✕ Subjects on insulin.
Where it's recruiting
Tucson
Source: ClinicalTrials.gov · NCT07627191 · last updated 2026-11-16